Evidence map›Paper›PMID 41599000›Full record

ReviewPathogens (Basel, Switzerland)2025

Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and Disputed

Siti Soidah, Toto Subroto, Irvan Faizal, Muhammad Yusuf

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Siti SoidahDoctoral Program in Biotechnology, Graduate School, Universitas Padjadjaran, Bandung 40132, Indonesia.ORCID 0000-0002-0650-6905
Toto SubrotoResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40132, Indonesia.ORCID 0000-0002-1629-407X
Irvan FaizalResearch Cente for Vaccine and Drugs, National Research and Innovation Agency Republic of Indonesia, Tangerang Selatan 15314, Indonesia.ORCID 0000-0002-7555-0678
Muhammad YusufResearch Center for Molecular Biotechnology and Bioinformatics, Universitas Padjadjaran, Bandung 40132, Indonesia.ORCID 0000-0003-1627-1553

Funding

This publication charge is funded by Unpad through the Indonesian Endowment Fund for Edu-cation (LPDP) on behalf of the Indonesian Ministry of Higher Education, Science and Technology and managed under the EQUITY Program Contract No. 4303/ B3/DT.03.08/2025 and 3927/UN6. RKT/HK.07.00/2025
6 · The paper itself

Abstract

Rifampicin-resistant tuberculosis (RR-TB) remains a major threat to global TB control, primarily driven by mutations in the

Indexed as

Bacterial ProteinsDNA-Directed RNA PolymerasesDrug Resistance, BacterialMutationMycobacterium tuberculosisRifampinTuberculosis, Multidrug-ResistantAntibiotics, AntitubercularAntitubercular AgentsHumansMicrobial Sensitivity TestsAntibiotics, AntitubercularAntitubercular AgentsBacterial ProteinsDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisdisputed mutationsmolecular diagnosticsMycobacterium tuberculosisrifampicin resistancerpoB mutationswhole-genome sequencing

Identifiers

PMID41599000
PMCPMC12844990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.